作者
David S. Ettinger,Douglas E. Wood,Dara L. Aisner,Wallace Akerley,Jessica R. Bauman,Ankit Bharat,Débora S. Bruno,Joe Y. Chang,Lucian R. Chirieac,Thomas A. D’Amico,Malcolm M. DeCamp,Thomas J. Dilling,Jonathan E. Dowell,Scott Gettinger,Travis E. Grotz,Matthew A. Gubens,Aparna Hegde,Rudy P. Lackner,Michael Lanuti,Jules Lin,Billy W. Loo,Christine M. Lovly,Fabien Maldonado,Erminia Massarelli,Daniel Morgensztern,Thomas Ng,Gregory A. Otterson,Jose M. Pacheco,Sandip Pravin Patel,Gregory J. Riely,Jonathan W. Riess,Steven E. Schild,Theresa A. Shapiro,Aditi P. Singh,James Stevenson,Alda L. Tam,Tawee Tanvetyanon,Jane Yanagawa,Stephen C. Yang,Edwin Yau,Kristina M. Gregory,Miranda Hughes
摘要
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommended management for patients with NSCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. Patients with metastatic lung cancer who are eligible for targeted therapies or immunotherapies are now surviving longer. This selection from the NCCN Guidelines for NSCLC focuses on targeted therapies for patients with metastatic NSCLC and actionable mutations.